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Peroxisome proliferators and thyroid hormones have a number of common metabolic effects. The possibility that the signal transduction pathways 
of both groups of effecters converge at the receptor level was investigated. It was shown that T3, specifically bound to the rat thyroid B-receptor, 
was not displaced to a sign&ant extent by ciprofibrate or bezaflbrate. No specific binding of T3 to the mouse peroxisome proliferator activated 
receptor could be demonstrated. In transactivation experiments peroxisome proliferators were unable to activate the thyroid receptor and T3 did 
not activate a chimeric receptor containing the ligand binding domain of the peroxisome proliferator activated receptor. It is concluded that 
peroxisome proliferators and thyroid hormone do not cross-react at the level of their nuclear receptors. 
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1. ~~ROD~~ION 
A number of reports have appeared in recent litera- 
ture indicating that peroxisome proliferators and thy- 
roid hormones have overlapping metabolic effects: both 
are hypolipidemic and calorigenic and both, in vitro as 
well as in vivo, induce enzymes that are classically con- 
sidered to be thyroid hormone dependent, e.g. malic 
enzyme, glycerol-3-phosphate dehydrogenase and S14 
(see [l] and references therein). The inductive effects of 
peroxisome proliferators are independent of the pres- 
ence of thyroid hormones and are, at least in some 
cases, the result of increases in the ~orrespon~ng 
mRNAs due to transcriptional activation of the respec- 
tive genes [2,3]. On the other hand, evidence for the 
peroxisome proliferative effect of thyroid hormones is 
conticting [3,4]. The capacity of peroxisome prolifera- 
tors to induce peroxisomal enzymes is not always corre- 
lated with their thyromimetic or hypolipidemic effects, 
implying distinct mechanisms [3]. Moreover, per- 
oxisome proliferators and thyroid hormones have dif- 
ferent tissue specificities, suggesting that both groups of 
effecters use different transduction pathways [1,3]. In 
some cases peroxisome proliferators have a higher in- 
ductive capacity than thyroid hormones [3] and their 
The cDNA for the mouse PPAR was obtained by PCR from mouse 
liver RNA and subcloned in the CDM expression vector. The rat 
thyroid #I-receptor (TR) expression vector was provided by D.D. 
Moore (Boston, USA). Reporter plasmids were constructed in the 
pUTKAT vector [ll]. The TR-PPAR chimera was generated using 
PCR with primers tlanking the ABC domains of the TR and the DEF 
domains of the PPAR. At the N-terminus of the D domain of the 
chiieric construct a serine residue was replaced by an a&nine an a 
histidine by an alanine. 
*Corresponding author. Fax: (32) (16) 28-3414. 
2.2. Other materials 
Abbreviations: PPAR, peroxisome proliferator activated receptor; TR, All other materials were of the highest purity available and were 
thyroid B-receptor; DMEM, Dulbecco’s Modified Eagle’s Medium; obtained from Boehringer-Mannbeim Belgium (Brussels, Belgium) or 
DMSO, dimethylsulfoxide; PBS, phosphate-buffered saline; D’lT, Sigma Chemical Co. (St. Louis, MO, USA). [‘251]T3 was purchased 
dithiothreitol; PMSF, phenyhnethanesulphonyltluoride; CAT, chlo- from DuPont-New England Nuclear (Brussels, Belgium). Ciprofi- 
ramphenicol acetyltransferase; TRE, thyroid hormone response ele- brate, bezaflbrate and metbylclofenapate were generous gifts from, 
ment. respectively, Winthrop Laboratories (Brussels, Belgium), Boehringer- 
effects can be additive [2], corroborating the thesis of 
independent mechanisms. 
Thyroid hormone action is mediated by specitic nu- 
clear receptors interacting with cognate nucleotide se- 
quences (response lements) in the promoter of affected 
genes [5,6]. Peroxisome proliferators appear to operate 
by a similar but less well-characterized mechanism: 
‘peroxisome proliferator activated receptors’ (PPARs) 
were recently isolated and found to be structurally re- 
lated to thyroid hormone receptors [7,8]. Respons ele- 
ments for PPARs have been described [9,10] but the 
endogenous ligand of this receptor remains elusive. 
In this paper we present evidence that peroxisome 
proliferators and thyroid hormones do not cross-react 
at the receptor level. 
2. EXPERIMENTAL 
2.1. Plasmids 
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Mannheim Belgium (Brussels, Belgium) and Imperial Chemical Indus- 
tries (Macclesfield, UK). 
2.3. Overexpression of TR and PPAR 
lo6 COS-M6 cells (American Type Culture Collection, Rockville, 
MD, USA) were seeded into 10 cm dishes in DMEM+lO% (v/v) 
newborn calf serum one day prior to transfection. The medium was 
changed to DMEM+lO% (v/v) NuSerum one hour before transfec- 
tion. Each dish was transfected with 5 yg receptor expression vector 
using the DEAE-dextran method [12]. Chloroquine (100 PM) was 
added to increase transfection efficiency. After 3.5 h of incubation, 
cells were shocked with 10% (v/v) DMSO and grown for 2 days in 
DMEM supplemented with 10% (v/v) charcoal-stripped calf serum. 
2.4. Preparation of a CO9M6 nuclear extract 
Cells were scraped in PBS, pelleted and swollen for 5 min on ice in 
25 mM KCl, 2 mM Mg-acetate, 1 mM DTT, 10 mM Tris-HCl, pH 
7.5. The suspension was triturated through a 25-gauge needle to lyse 
the cells. The nuclei were pelleted and resuspended in a hypertonic 
buffer (0.4 M KCl, 2 mM Mg-acetate, 1 mM D’IT, 0.5 mM PMSF, 
lOpg/pl leupeptin, 10 mM Tris-HCl, pH 7.5). After 10 min on ice, the 
nuclei were homogenised and left to stand for another 10 min on ice. 
The crude nuclear extract was cleared by centrifugation for 10 min at 
16,000 x g and diluted with one volume of 0.1 M KCl, 20% (v/v) 
glycerol, 1 mM DTI; 0.5 mM PMSF, 90 mM Tris-HCl, pH 7.5, to 
create optimal binding conditions. 
2.5. Binding assay 
The nuclear extract containing TR or PPAR was incubated over- 
night at 4°C with 3 x lo-’ M [iz51]T3 (2200 Ciimmol) in 0.25 M KCl, 
10% (v/v) glycerol, 1 mM DTT, 0.5 mM PMSF, 5 pg/pl leupeptin, 50 
mM Tris-HCl, pH 7.5 (binding buffer), in the presence or absence of 
an excess of cold competitor (T3, ciprofibrate or bezafibrate). Free 
[rZI]T3 was separated from protein-bound [‘*‘I]T3 by adsorption to 
1.25% (w/v) dextran-coated charcoal, suspended in binding buffer. 
Radioactive T3 bound to the receptor was measured by counting of 
the supematant. The displacement of [?lT3 from the receptor by the 
cold competitor was used as a measure for specific binding. 
2.6. Cell culture and transfections 
JEG-3 cells (American Type Culture Collection, Rockville, MD, 
USA) were seeded into 6 cm dishes in DMEM supplemented with 10% 
(v/v) charcoal-stripped fetal bovine serum one day prior to transfec- 
tion. Transfections were carried out using calcium phosphate precipi- 
tation with 6 pg of reporter plasmid, 3 ,ug of expression plasmid and 
5 pg of pSV2APAP (coding for alkaline phosphatase) for normaliza- 
tion purposes. After 18-24 h, cells were shocked with 20% (v/v) DMSO 
and refed with DMEM containing charcoal-stripped serum and either 
vehicle (DMSO), T3, ciprofibrate or methylclofenapate. After 2 days, 
cell extracts were prepared and CAT activities were analyzed as de- 
scribed by Brent et al. [12]. Alkaline phosphatase activity was meas- 
ured by incubating 2 pl of cell extract with 1 ml of 5 mM p-nitrophen- 
ylphosphate in 1 M diethanolamine buffer, pH 9.8,0.28 M NaCl, 0.5 
mM MgCl, for 1 h at 30°C and reading absorbance at 405 run. 
3. RESULTS AND DISCUSSION 
We first wanted to investigate possible displacement 
by peroxisome proliferators of T3 bound to the TR and 
possible binding of T3 to the PPAR. 
COS-M6 cells were transiently transfected with TR 
and nuclear extracts were prepared. The extracts were 
incubated with 3 x 10T9 M [lz51]T3, in the absence or 
presence of cold ‘competitor’, and bound labeled T3 
was measured. Table I shows the results of a typical 
experiment. In the absence of competitor, approx. 
Table I 
Displacement of [“‘IIT (3 x lo-’ M) from the TR in a nuclear extract 
prepared from COSM6 cells transiently transfected with TR 
Competitor Displacement of 
[rZ51]T3 from the 
TR 
T3 
Ciprofibrate 
Bezafibrate 
3xlW’M 100 
3 x lO-7 M a 
3 x lo4 M 8 
3 x 10.’ M 15 
3 x lo-’ M 0 
3 x lO-6 M 0 
3 x lO-5 M 12 
The radioactivity displaced is expressed relative to the value displaced 
by cold T3, which was arbitrarily set at 100. See text for more details. 
The experiment was performed twice with equivalent results; data 
from one representative experiment are given. 
115,000 dpm of label bound to the nuclear extract. Cold 
T3 (lOO-fold excess) displaced approx. 63,000 dpm, 
clearly attesting to specific binding of T3. It can be seen 
that ciprofibrate and bezafibrate, up to a lO,OOO-fold 
excess, displaced very little specifically bound T3. This 
indicates that both compounds, which are very potent 
peroxisome proliferators, do not bind to the TR, at least 
under the given conditions. This in agreement with the 
results of Hertz et al. [3] who could not show displace- 
ment of T3 by bezafibrate in a nuclear extract from rat 
liver. 
In control experiments, COS-MB cells were trans- 
fected with the parental expression vector. Specific 
binding of T3 was much lower: approx. 19,000 dpm 
displaced on a total of 72,000 dpm; this most probably 
corresponds to endogenous thyroid hormone receptor 
present in the nuclei of the cells. 
When COS-M6 cells were transiently transfected with 
PPAR no specific binding of T3, either in presence or 
absence of peroxisome proliferators (ciprofibrate or 
bezafibrate), could be demonstrated (results not 
shown). 
In order to confirm these results transactivation ex- 
Table II 
Activation of TR in JEG3 cells transiently transfected with TR and 
a TRE-driven CAT reporter 
Condition Fold induction 
of CAT 
Control (DMSO) 1.0 
Ciprofibrate 10“ M 0.8 
Ciprofibrate lOA M 0.9 
T3 lo+’ M 5.3 
T3 10-s M 29.6 
The induction of CAT activity is expressed relative to the control, 
which is arbitrarily set at 1. See text for more details. The experiment 
was performed twice with equivalent results; data from one represen- 
tative experiment are given. 
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Table III 
Activation of TR-PPAR in JEG-3 cells transienfty ransftied with the 
chimeric TR-PPAR receptor and a TREdriven CAT reporter 
Conaition Fold induction of 
CAT 
Control @MS@ I.0 
T3 1@ M 1.0 
Me~y~ciofenap~te IF5 M 1.7 
Meth~~ciof~~~~ I@ M x3 
The inductism of CAT actify is expressed relative to the confrol, 
which is arbitrarily set at I. See text for more details. The experiment 
was petiormed twice with equiv&ent results; data from one represen- 
nred (Table III). As expected, methyl~lof~apate s imu- 
lated the expression of CAT, in a dose dependent man- 
ner, but T3 was without effect, 
It can be concluded that there is no evidence for 
cross-reactivity of TR and PPAR with respect to their 
activating ligands. 
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